# US 2013/0251631 A1 · Low molecular weight thyroid stimulating hormone receptor (tshr) agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251631 A1
- Document ID: US20130251631A1
- Status: Published application
- Kind: A1
- Application number: 13/897,330
- Filed: 2013-05-17
- Published: 2013-09-26
- Earliest claimed: 2011-04-19
- Assignees: Forschungsverbund Berlin E.V.; The Government of the United States of America as represented by the Secretary of the Department of
- Applicants: Forschungsverbund Berlin E.V.; The Government of the United States of America as represented by the Secretary of the Department of
- Inventors: Marvin C. Gershengorn; Susanne Neumann; Bruce M. Raaka; Craig J. Thomas; James Inglese; Noel T. Southall; Steven Titus; Wei Zheng; Wenwei Huang; Gerd Krause; Gunnar Kleinau
- Web page: https://patentgrep.com/patent/US20130251631A1

## CPC

- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 49/0004: {Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions}
- A61K 51/00: Preparations containing radioactive substances for use in therapy or testing in vivo
- A61P 19/00: Drugs for skeletal disorders
- A61P 35/00: Antineoplastic agents
- C07D 239/91: with aryl or aralkyl radicals attached in position 2 or 3
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.

## Claims

### Claim 1

A compound having formula I:
or a pharmaceutically acceptable salt thereof, wherein:
(a) R1-R4 are each independently H, hydroxyl, alkyl, alkoxy, aminocarbonyl, or halogen;
R5 is H, alkyl, aralkyl, or aminocarbonyl;
A represents —N═C(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above) or —NH—CH(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above);
R15 is represented by formula II:
wherein:
R6-R9 are each independently H, hydroxyl, alkyl, or alkoxy;
R10, R11, R13 and R14 are each independently H;
R12 is acetamido; and
X is O, S or N(H);
with the proviso that the compound of formula I is not
or
(b) R1-R3 are each independently H, hydroxyl, alkyl, alkoxy, aminocarbonyl, or halogen;
R4 is hydroxyl;
R5 is H, alkyl, aryl, aralkyl, or aminocarbonyl;
A represents —N═C(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above) or —NH—CH(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above);
R15 is represented by formula II:
wherein:
R6-R9 are each independently H, hydroxyl, alkyl, or alkoxy;
R10, R11, R13 and R14 are each independently H;
R12 is acetamido; and
X is O, S or N(H); or
(c) R1-R4 are each independently H, hydroxyl, alkyl, alkoxy, aminocarbonyl, or halogen;
R5 is H, alkyl, aryl, aralkyl, or aminocarbonyl;
A represents —N═C(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above);
R15 is represented by formula II:
wherein:
R6-R9 are each independently H, hydroxyl, alkyl, or alkoxy;
R10, R11, R13 and R14 are each independently H;
R12 is acetamido; and
X is O, S or N(H).

### Claim 2 (depends on 1)

The compound of claim 1, wherein R5 is aralkyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R5 is:

### Claim 4 (depends on 1)

The compound of claim 1, wherein R9 is C1-C4 alkoxy.

### Claim 5 (depends on 1)

The compound of claim 1, wherein X is O.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R1-R4 are each independently H.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R15 is represented by formula III:

### Claim 8 (depends on 1)

The compound of claim 1, wherein the compound is:

### Claim 9 (depends on 1)

The compound of claim 1, wherein the compound is:

### Claim 10 (depends on 1)

The compound of claim 1, wherein the compound is:

### Claim 11 (depends on 1)

The compound of claim 1, wherein the compound is:

### Claim 12 (depends on 1)

The compound of claim 1, wherein the compound is:

### Claim 13 (depends on 1)

The compound of claim 1, wherein the compound is a thyroid stimulating hormone receptor agonist.

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound is a selective thyroid stimulating hormone receptor agonist.

### Claim 15 (depends on 1)

The compound of claim 1, wherein R5 is aralkyl;
R9 is methoxy; and
X is O or S.

### Claim 16

A method for detecting thyroid cancer in a subject, comprising administering to the subject in need thereof a diagnostically effective amount of at least one compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1-R4 are each independently H, hydroxyl, alkyl, alkoxy, aminocarbonyl, or halogen;
R5 is H, alkyl, aryl, aralkyl, or aminocarbonyl;
A represents —N═C(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above) or —NH—CH(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above);
R15 is represented by formula II:
wherein:
R6-R9 are each independently H, hydroxyl, alkyl, or alkoxy;
R10, R11, R13 and R14 are each independently H;
R12 is acetamido; and
X is O, S or N(H).

### Claim 17 (depends on 16)

The method of claim 16, wherein the subject has undergone thyroidectomy for well-differentiated thyroid cancer.

### Claim 18 (depends on 16)

The method of claim 16, wherein administration of the at least one compound of formula I enhances iodine uptake by thyroid cells.

### Claim 19

A method for treating thyroid cancer in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of at least one compound having a formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1-R4 are each independently H, hydroxyl, alkyl, alkoxy, aminocarbonyl, or halogen;
R5 is H, alkyl, aryl, aralkyl, or aminocarbonyl;
A represents —N═C(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above) or —NH—CH(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above);
R15 is represented by formula II:
wherein:
R6-R9 are each independently H, hydroxyl, alkyl, or alkoxy;
R10, R11, R13 and R14 are each independently H;
R12 is acetamido; and
X is O, S or N(H).

### Claim 20 (depends on 21)

The method of claim 21, further comprising co-administering radioiodine with the compound of formula I to ablate thyroid remnants following near-total thyroidectomy in a subject without evidence of metastatic disease.
